The present invention relates to methods for treating pathological conditions associated with Helicobacter sp infections, specifically H.pylori infection. The present invention further relates to methods for treating pathologies characterized by excess gastric acid secretion. The methods of the present invention com...

The present invention relates to methods and compositions for treating pathological conditions associated with ferrous-dependent bacteria, such as, Helicobacter pylori in which high intracellular ferrous iron concentration is required for their survival and pathogenesis. The compositions of the invention comprise en...

The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compo...

The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more aliphatic carboxylic acid derivative molecules which activate parietal cells, wherein the derivatives possess delayed or sustai...

The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor, pentagastrin (PG) or a PG analogue as an activator of parietal cells in the gastric lumen. In a preferred embodiment, the composition further ...